NO20054136L - Imidazol-4-yl-etynyl-pyridin-derivater - Google Patents

Imidazol-4-yl-etynyl-pyridin-derivater

Info

Publication number: NO20054136L
Authority: NO; Norway
Prior art keywords: imidazol; pyridine derivatives; ylethynyl; disease; alkyl
Prior art date: 2003-03-10

Application number

NO20054136A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054136D0 (no

Inventor

Sabine Kolczewski

Bernd Buettelmann

Georg Jaeschke

Eric Vieira

Simona Maria Ceccarelli

Richard Hugh Phillip Porter

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-10

Filing date

2005-09-06

Publication date

2005-09-26

2005-09-06 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2005-09-06 Publication of NO20054136D0 publication Critical patent/NO20054136D0/no

2005-09-26 Publication of NO20054136L publication Critical patent/NO20054136L/no

Links

DEJSKFIZYYGXSU-UHFFFAOYSA-N 2-ethynyl-3-(1h-imidazol-5-yl)pyridine Chemical class C#CC1=NC=CC=C1C1=CN=CN1 DEJSKFIZYYGXSU-UHFFFAOYSA-N 0.000 title 1
208000024827 Alzheimer disease Diseases 0.000 abstract 2
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
206010039966 Senile dementia Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
230000003412 degenerative effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
206010013663 drug dependence Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
210000000653 nervous system Anatomy 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
208000020016 psychiatric disease Diseases 0.000 abstract 1
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1
230000000472 traumatic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20054136A 2003-03-10 2005-09-06 Imidazol-4-yl-etynyl-pyridin-derivater NO20054136L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03004952		2003-03-10
PCT/EP2004/002276 WO2004080998A1 (fr)	2003-03-10	2004-03-05	Derives de l'imidazol-4-yl-ethynyl-pyridine

Publications (2)

Publication Number	Publication Date
NO20054136D0 NO20054136D0 (no)	2005-09-06
NO20054136L true NO20054136L (no)	2005-09-26

Family

ID=32981724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054136A NO20054136L (no)	2003-03-10	2005-09-06	Imidazol-4-yl-etynyl-pyridin-derivater

Country Status (30)

Country	Link
US (1)	US7153874B2 (fr)
EP (1)	EP1606277B8 (fr)
JP (1)	JP4404896B2 (fr)
KR (1)	KR100742019B1 (fr)
CN (1)	CN100358889C (fr)
AR (1)	AR043501A1 (fr)
AT (1)	ATE395345T1 (fr)
AU (1)	AU2004220382B2 (fr)
BR (1)	BRPI0408093A (fr)
CA (1)	CA2516682C (fr)
CL (1)	CL2004000449A1 (fr)
CO (1)	CO5601027A2 (fr)
DE (1)	DE602004013746D1 (fr)
DK (1)	DK1606277T3 (fr)
ES (1)	ES2305739T3 (fr)
HR (1)	HRP20050774A2 (fr)
IL (1)	IL170129A (fr)
MX (1)	MXPA05009524A (fr)
MY (1)	MY135491A (fr)
NO (1)	NO20054136L (fr)
NZ (1)	NZ541643A (fr)
PA (1)	PA8597301A1 (fr)
PE (1)	PE20041061A1 (fr)
PL (1)	PL1606277T3 (fr)
PT (1)	PT1606277E (fr)
RU (1)	RU2342383C2 (fr)
SI (1)	SI1606277T1 (fr)
TW (1)	TWI292318B (fr)
WO (1)	WO2004080998A1 (fr)
ZA (1)	ZA200506834B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA80888C2 (en) *	2003-06-05	2007-11-12	Hoffmann La Roche	Imidazole derivatives as glutmate receptor antagonists
US7452909B2 (en) *	2003-09-04	2008-11-18	Hoffman-La Roche Inc.	Imidazole derivatives
EP1756086B1 (fr) *	2004-06-01	2008-06-04	F.Hoffmann-La Roche Ag	Pyridin-4-yl-ethynyl-imidazoles et pyrazoles, antagonistes du recepteur mglur5
HRP20080363T3 (hr)	2004-06-01	2008-09-30	F. Hoffmann - La Roche Ag	Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
EP2275096A3 (fr)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenese par modulation des recepteurs muscariniques
EP2258357A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse avec inhibiteur de l'acetylcholinestérase
WO2007047978A2 (fr)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation de la neurogenese par inhibition de la pde
EP2314289A1 (fr)	2005-10-31	2011-04-27	Braincells, Inc.	Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
DE102006011574A1 (de) *	2006-03-10	2007-10-31	Grünenthal GmbH	Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
EP2021000A2 (fr)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenèse par modulation de l'angiotensine
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
WO2008030651A1 (fr) *	2006-09-08	2008-03-13	Braincells, Inc.	Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
AU2007336369B2 (en)	2006-12-21	2013-01-17	F. Hoffmann-La Roche Ag	Polymorphs of a mGluR5 receptor antagonist
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
US8334287B2 (en)	2009-07-17	2012-12-18	Hoffmann-La Roche Inc.	Imidazoles
US8586581B2 (en) *	2009-12-17	2013-11-19	Hoffmann-La Roche Inc	Ethynyl compounds useful for treatment of CNS disorders
EA022019B1 (ru)	2011-04-26	2015-10-30	Ф.Хоффманн-Ля Рош Аг	Этинильные производные в качестве положительных аллостерических модуляторов mglur5
UA116023C2 (uk)	2013-07-08	2018-01-25	Ф. Хоффманн-Ля Рош Аг	Етинільні похідні як антагоністи метаботропного глутаматного рецептора
WO2017117708A1 (fr)	2016-01-05	2017-07-13	Hua Medicine (Shanghai) Ltd.	Dérivés de pyrazole
TW201837026A (zh)	2017-01-10	2018-10-16	德商拜耳廠股份有限公司	作為除害劑之雜環衍生物（二）
KR102515694B1 (ko)	2017-01-10	2023-03-29	바이엘 악티엔게젤샤프트	해충 방제제로서의 헤테로사이클 유도체
CN114746408B (zh) *	2019-12-02	2025-02-14	豪夫迈·罗氏有限公司	炔基-(杂芳基)-甲酰胺hcn1抑制剂
CN111416154B (zh) *	2020-05-22	2021-08-06	松山湖材料实验室	高电压锂离子电池电解液硅基吡啶添加剂、电解液及其电池
MX2022015407A (es)	2020-06-05	2023-05-16	Noema Pharma Ag	Metodos de tratamiento del complejo de esclerosis tuberosa.
WO2022207479A1 (fr)	2021-03-27	2022-10-06	Syngenta Crop Protection Ag	Dérivés d'amide isonicotinique microbiocides
JP2024541419A (ja)	2021-11-19	2024-11-08	シンジェンタクロッププロテクションアクチェンゲゼルシャフト	殺微生物イソニコチンアミド誘導体
WO2024132901A1 (fr)	2022-12-19	2024-06-27	Syngenta Crop Protection Ag	Dérivés microbiocides de pyridazine dihydrooxadiazine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3303199A (en)	1963-07-15	1967-02-07	Geigy Chem Corp	Certain imidazolone derivatives and process for making same
US3341548A (en)	1964-04-29	1967-09-12	Hoffmann La Roche	Nitroimidazoles and their preparation
DE2035905A1 (de)	1970-07-20	1972-02-03	Chemische Fabrik Stockhausen & Cie.,4150Krefeld	Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (fr)	1981-02-27	1984-09-18	Walter Hunkeler	Imidazodiazepines
US4711962A (en)	1984-10-18	1987-12-08	Stauffer Chemical Company	Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
US4868181A (en) *	1986-08-04	1989-09-19	E. I. Du Pont De Nemours And Company	1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
US4882343A (en) *	1987-08-28	1989-11-21	G. D. Searle & Co.	Biarylalkylimidazole derivatives as anti-depressants
KR0163595B1 (ko)	1989-06-30	1998-12-01	미리암디, 메코너헤이	치환된 이미다졸
TW544448B (en) *	1997-07-11	2003-08-01	Novartis Ag	Pyridine derivatives
ID28529A (id)	1997-08-14	2001-05-31	Hoffmann La Roche	Vinileter heterosiklik untuk gangguan neurologi
JP4815083B2 (ja)	1999-08-31	2011-11-16	メルク・シャープ・エンド・ドーム・コーポレイション	複素環化合物およびそれの使用方法
NZ525917A (en)	2000-12-04	2005-11-25	F	Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists and their use in treating mGLuR5 receptor mediated disorders
EP1458385A4 (fr) *	2001-12-19	2005-12-21	Merck & Co Inc	Imidazoles substitues par heteroaryle modulateurs du recepteur metabotropique du glutamate de type 5

2004
- 2004-03-04 TW TW093105737A patent/TWI292318B/zh not_active IP Right Cessation
- 2004-03-05 CA CA002516682A patent/CA2516682C/fr not_active Expired - Fee Related
- 2004-03-05 RU RU2005131165/04A patent/RU2342383C2/ru not_active IP Right Cessation
- 2004-03-05 BR BRPI0408093-9A patent/BRPI0408093A/pt not_active IP Right Cessation
- 2004-03-05 AT AT04717578T patent/ATE395345T1/de active
- 2004-03-05 AU AU2004220382A patent/AU2004220382B2/en not_active Ceased
- 2004-03-05 ES ES04717578T patent/ES2305739T3/es not_active Expired - Lifetime
- 2004-03-05 HR HR20050774A patent/HRP20050774A2/xx not_active Application Discontinuation
- 2004-03-05 MX MXPA05009524A patent/MXPA05009524A/es active IP Right Grant
- 2004-03-05 CN CNB2004800065725A patent/CN100358889C/zh not_active Expired - Fee Related
- 2004-03-05 PT PT04717578T patent/PT1606277E/pt unknown
- 2004-03-05 DK DK04717578T patent/DK1606277T3/da active
- 2004-03-05 NZ NZ541643A patent/NZ541643A/en unknown
- 2004-03-05 JP JP2006504558A patent/JP4404896B2/ja not_active Expired - Fee Related
- 2004-03-05 EP EP04717578A patent/EP1606277B8/fr not_active Expired - Lifetime
- 2004-03-05 DE DE602004013746T patent/DE602004013746D1/de not_active Expired - Lifetime
- 2004-03-05 SI SI200430735T patent/SI1606277T1/sl unknown
- 2004-03-05 PA PA20048597301A patent/PA8597301A1/es unknown
- 2004-03-05 KR KR1020057016753A patent/KR100742019B1/ko not_active Expired - Fee Related
- 2004-03-05 PL PL04717578T patent/PL1606277T3/pl unknown
- 2004-03-05 WO PCT/EP2004/002276 patent/WO2004080998A1/fr not_active Ceased
- 2004-03-08 CL CL200400449A patent/CL2004000449A1/es unknown
- 2004-03-08 US US10/795,619 patent/US7153874B2/en not_active Expired - Fee Related
- 2004-03-08 PE PE2004000252A patent/PE20041061A1/es not_active Application Discontinuation
- 2004-03-08 AR ARP040100722A patent/AR043501A1/es not_active Application Discontinuation
- 2004-03-09 MY MYPI20040806A patent/MY135491A/en unknown
2005
- 2005-08-04 IL IL170129A patent/IL170129A/en not_active IP Right Cessation
- 2005-08-25 ZA ZA200506834A patent/ZA200506834B/en unknown
- 2005-08-25 CO CO05085015A patent/CO5601027A2/es active IP Right Grant
- 2005-09-06 NO NO20054136A patent/NO20054136L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20050109074A (ko)	2005-11-17
PA8597301A1 (es)	2004-09-16
WO2004080998A1 (fr)	2004-09-23
JP2006519802A (ja)	2006-08-31
CN100358889C (zh)	2008-01-02
CO5601027A2 (es)	2006-01-31
US7153874B2 (en)	2006-12-26
DE602004013746D1 (de)	2008-06-26
ES2305739T3 (es)	2008-11-01
CN1759111A (zh)	2006-04-12
BRPI0408093A (pt)	2006-02-14
US20040229917A1 (en)	2004-11-18
MY135491A (en)	2008-04-30
PT1606277E (pt)	2008-07-08
NZ541643A (en)	2008-03-28
AU2004220382B2 (en)	2007-08-02
JP4404896B2 (ja)	2010-01-27
TWI292318B (en)	2008-01-11
EP1606277B8 (fr)	2008-10-15
CA2516682C (fr)	2010-02-02
HK1089443A1 (zh)	2006-12-01
PL1606277T3 (pl)	2008-10-31
ZA200506834B (en)	2006-05-31
AR043501A1 (es)	2005-08-03
RU2342383C2 (ru)	2008-12-27
RU2005131165A (ru)	2007-04-20
ATE395345T1 (de)	2008-05-15
NO20054136D0 (no)	2005-09-06
MXPA05009524A (es)	2005-10-18
TW200423935A (en)	2004-11-16
SI1606277T1 (sl)	2008-08-31
CL2004000449A1 (es)	2005-01-07
DK1606277T3 (da)	2008-08-18
PE20041061A1 (es)	2005-01-22
KR100742019B1 (ko)	2007-07-23
EP1606277A1 (fr)	2005-12-21
CA2516682A1 (fr)	2004-09-23
HRP20050774A2 (en)	2006-09-30
AU2004220382A1 (en)	2004-09-23
EP1606277B1 (fr)	2008-05-14
IL170129A (en)	2013-02-28

Legal Events

Date	Code	Title	Description
2011-10-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
MXPA05009524A (es)	2005-10-18	Derivados de imidazol-4-il-etinil-piridina.
MA27134A1 (fr)	2005-01-03	Derives diarylcycloalkyle, leur procede de preparation et leur utilisation en tant qu'activateurs des ppar
NO20082768L (no)	2008-06-24	Levodopa prodroge mesylat, sammensetninger og anvendelser derav
WO2007127505A3 (fr)	2007-12-27	Composés chimiques
CY1122238T1 (el)	2020-07-31	Νεα 1-ναφθυλ-3-αζαδικυκλο[3.1.0]εξανia: παρασκευη και χρηση για τη θεραπεια νευροψυχιατρικων διαταραχων
NO20056130L (no)	2006-02-27	Nye substituerte 3-svovelindoler
CY1111206T1 (el)	2015-06-11	Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
NO20083958L (no)	2004-02-09	Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
NO20100496L (no)	2001-12-04	Derivater av venlafaksin og anvendelse av samme
EA200500250A1 (ru)	2005-12-29	Аналоги тиомолибдата и их применение
CY1110745T1 (el)	2015-06-10	Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
WO2004071442A3 (fr)	2004-10-28	Nouveaux composes bicycliques et compositions associees
NO20025517D0 (no)	2002-11-18	Triazolderivater
PL1706113T3 (pl)	2009-07-31	Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu
NO20060328L (no)	2006-02-17	Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
DK1578740T3 (da)	2007-07-30	1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
BR0316723A (pt)	2005-10-18	Derivados de anilinopirazol úteis para o tratamento de diabetes
CY1110775T1 (el)	2015-06-10	Υποκατεστημενα αμιδια του θειενοπυρρολιου του καρβοξυλικου οξεος, αμιδια της πυρρολοθειαζολης του καρβοξυλικου οξεος και σχετικα αναλογα ως αναστολεις της κινασης i εψιλον της καζεϊνης
NO20082679L (no)	2008-06-10	Sammensetning og fremgangsmate for a behandle CNS lidelser
DK1272208T3 (da)	2011-10-31	Anvendelse af VEGF 165 og homologer til at behandle neuron-sygdomme
WO2004022540A3 (fr)	2004-07-01	Compose de pyridazinone et son utilisation pharmaceutique
NO20060020L (no)	2006-03-03	3-fluorpiperidiner som NMDA/NR2B-antagonister
WO2022204362A3 (fr)	2022-11-24	Compositions et méthodes de traitement d'un trouble neurodégénératif ou du développement
NO20056116L (no)	2006-02-24	Tiowolframatanaloger og anvendelse av slike
WO2005041856A3 (fr)	2006-08-10	Utilsiation de 2-thia-dibenzo[e, h]azulenes permettant la fabrication de formulations pharmaceutiques pour le traitement et la prevention des maladies et des troubles du systeme nerveux central